Peptide Profile

CJC-1295

Growth Hormone-Releasing Hormone Analog

Research Only10 sourcesShop CJC-1295

Overview

Composition

Synthetic analog of growth hormone-releasing hormone (GHRH), consisting of 30 amino acids with modifications for enhanced stability and prolonged activity

Mechanism of Action

Stimulates the pituitary gland to increase endogenous growth hormone (GH) secretion in a pulsatile manner, elevating insulin-like growth factor-1 (IGF-1) levels

Primary Effects

Studied for GH/IGF-1 signaling, body-composition endpoints, recovery markers, and sleep-related outcomes; DAC-linked and non-DAC variants differ in duration of action

Discovery & Background

Developed by ConjuChem Biotechnologies in the early 2000s as a long-acting GHRH analog, incorporating amino acid substitutions for resistance to degradation and (in the DAC form) an albumin-binding moiety to extend circulation time

Early clinical studies in the 2000s evaluated the DAC-linked form for sustained GH and IGF-1 signaling; modified GRF 1-29 remains a shorter-acting related analog.

Investigational, not FDA-approved for therapeutic use; commercial wellness and performance claims exceed the available outcomes evidence

Research Overview

Human evidence is centered on small early studies of CJC-1295 with DAC and broader growth-hormone secretagogue physiology.

01
CJC-1295 with DAC produced sustained GH and IGF-1 elevations in early human research
02
Half-life ~5.8–8.1 days for CJC-1295 with DAC
03
Evidence for body-composition or recovery claims is indirect and not supported by large outcomes trials
04
CJC-1295 without DAC (Mod GRF 1-29) has shorter half-life (~30 minutes), mimicking more natural GH pulses
05
Preclinical/animal models confirm normalization of growth/composition in GH-deficient contexts
06
GH stimulation does not establish safety or effectiveness for body-composition, recovery, or longevity claims
07
Large-scale trials are limited; evidence relies heavily on early studies and uncontrolled reports

Not approved for medical use; off-label exploration focuses on body composition and recovery

Safety Considerations

Monitoring

IGF-1 levels
Energy and vitality
Sleep quality
Body composition changes
Bloodwork for hormonal balance

Side Effects

Common

Generally well-tolerated
Possible water retention
Headache or flushing has been reported
Mild fatigue or transient GH-related effects (e.g., numbness)

DAC-Specific

DAC version may cause prolonged elevation leading to desensitization concerns

Contraindications

Limited data; avoid in active cancer
Diabetes without oversight
Pituitary issues
Those with GH-sensitive conditions should consult a healthcare provider

Educational Notice

CJC-1295 can raise GH/IGF-1 in early human studies, especially in DAC-linked form, but clinical outcome evidence remains limited. It is not FDA-approved, and claims about recovery, body composition, performance, or longevity are not established by large trials. Use decisions require qualified medical oversight and monitoring.

References